Department of Drug Sciences, University of Pavia, Viale Taramelli 12, 27100, Pavia, Italy; Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) - Helmholtz Centre for Infection Research (HZI), Campus building E8.1, 66123 Saarbrücken, Germany; Department of Pharmacy, Saarland University, Campus Building E8.1, 66123 Saarbrücken, Germany.
Department of Drug Sciences, University of Pavia, Viale Taramelli 12, 27100, Pavia, Italy.
Bioorg Chem. 2021 Nov;116:105305. doi: 10.1016/j.bioorg.2021.105305. Epub 2021 Aug 26.
Hu proteins are members of the RNA-binding protein (RBP) family and play a pivotal role in the regulation of post-transcriptional processes. Through interaction with selected mRNAs, RBPs regulate their function and stability; as a consequence, RBP dysregulation can cause abnormal translation of key proteins involved in several pathologies. In the past few years, this observation has sparked interest to develop new treatments against these pathologies by using small molecules able to modulate RBP activity. Among the four Hu proteins, we have directed our efforts towards the isoform HuR, which is mainly involved in cancer, inflammation and retinopathy. Aimed at developing compounds able to modulate the stability of HuR-mRNA complexes, in the present work, we applied a biophysical fragment screening by assessing a library of halogen-enriched heterocyclic fragments (HEFLibs) via Surface Plasmon Resonance (SPR) and Saturation Transfer Difference (STD) NMR to select promising fragments able to interact with HuR. One selected fragment and a few commercially available congeners were exploited to design and synthesize focused analogues of compound N-(3-chlorobenzyl)-N-(3,5-dihydroxyphenethyl)-4-hydroxybenzamide (1), our previously reported hit. STDNMR spectroscopy, molecular modeling, and SPR offered further insight into the HuR-small molecule interaction and showed that fragment-based approaches represent a promising and yet underexplored strategy to tackle such unusual targets. Lastly, fluorescence polarization (FP) studies revealed the capability of the new compounds to interfere with the formation of the HuR-mRNA complex. This is, to our knowledge, the first fragment-based campaign performed on the Hu protein class, and one of the few examples in the larger RBP field and constitutes an important step in the quest for the rational modulation of RBPs and related RNA functions by small molecules.
Hu 蛋白是 RNA 结合蛋白 (RBP) 家族的成员,在调节转录后过程中发挥关键作用。通过与选定的 mRNA 相互作用,RBPs 调节其功能和稳定性;因此,RBP 失调可能导致涉及几种病理学的关键蛋白质的翻译异常。在过去的几年中,这一观察结果激发了人们开发新的治疗方法的兴趣,这些方法通过使用能够调节 RBP 活性的小分子来治疗这些病理学。在这四种 Hu 蛋白中,我们将精力集中在 HuR 异构体上,它主要参与癌症、炎症和视网膜病变。为了开发能够调节 HuR-mRNA 复合物稳定性的化合物,在本工作中,我们通过表面等离子体共振 (SPR) 和饱和转移差 (STD) NMR 评估卤代杂环片段文库 (HEFLibs) ,应用了一种生物物理片段筛选方法,以选择有希望与 HuR 相互作用的片段。选择了一个片段和几个市售的类似物,用于设计和合成我们之前报道的命中化合物 N-(3-氯苄基)-N-(3,5-二羟基苯乙基)-4-羟基苯甲酰胺 (1) 的聚焦类似物。STD NMR 光谱、分子建模和 SPR 进一步深入了解了 HuR-小分子相互作用,并表明基于片段的方法代表了一种有前途但尚未充分探索的策略,可以解决此类不寻常的靶标。最后,荧光偏振 (FP) 研究表明,新化合物能够干扰 HuR-mRNA 复合物的形成。据我们所知,这是首次针对 Hu 蛋白类进行的基于片段的研究,也是在更大的 RBP 领域中为数不多的例子之一,这是通过小分子对 RBPs 和相关 RNA 功能进行理性调节的探索中的重要一步。